Brainomix

Investor: Parkwalk Advisors, Hostplus (via IP Group Hostplus Innovation Fund), Modi Ventures

Brainomix, an Oxford-based developer specializing in AI imaging tools for stroke and lung fibrosis, has secured an additional £4.8 million in an extension to its Series C funding round. This new capital will be used to expand the company's US operations and accelerate the deployment of its AI imaging platforms, Brainomix 360 Stroke and e-Lung, across hospitals.Summary of transaction details:Value: £4.8 millionSector: Healthcare & BiotechAdvisor: N/AKey Entities: Brainomix (Target); Parkwalk Advisors, Hostplus (via IP Group Hostplus Innovation Fund), Modi Ventures (Investors)Location: Oxford, UK (Target company base)Note: The investment highlights continued support from existing investors and the entry of a new US-based investor, underscoring strong confidence in Brainomix's innovative AI solutions for critical medical conditions and its growth trajectory in key markets.

Investor: Parkwalk Advisors, Boehringer Ingelheim Venture Fund, Hostplus

Brainomix, a leading developer of AI-powered imaging tools for stroke and lung fibrosis, has successfully completed a £14 million ($18 million) Series C investment round. The funding round was co-led by existing investors Parkwalk Advisors and Boehringer Ingelheim Venture Fund (BIVF), alongside new investor Hostplus via the IP Group Hostplus Innovation Fund. The round also saw support from LifeSci Capital.Summary of transaction details:Value: £14 million ($18 million)Sector: Healthcare & Biotech (AI Imaging)Advisor: LifeSci CapitalKey Entities: Brainomix (Target), Parkwalk Advisors (Lead Investor), Boehringer Ingelheim Venture Fund (Lead Investor), Hostplus (Lead Investor)Location: Oxford, UK, and Chicago, USA (Target Operations)Note: This investment will enable Brainomix to accelerate its commercial expansion into the US market following ten recent FDA clearances and to advance its portfolio of AI-powered technology in new therapeutic areas, ultimately facilitating faster diagnosis and increasing access to life-saving treatments.